{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-001255","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2021-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.117555+00:00","generated_at":"2026-06-28T18:16:46.817628+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"USANA Q3 net sales $274.4M, EPS $1.36; reiterates FY2021 outlook","bullets":["Net sales $274.4M (-8% YoY); diluted EPS $1.36 (-6% YoY).","Active customers 576,000 (-11% YoY); Greater China active customers -13% YoY.","Reiterates FY2021 net sales $1.18-$1.20B, EPS $5.80-$6.00; expects ~$130M free cash flow.","Cash $249M, no debt; repurchased 523k shares for $50M, $137M remaining under authorization.","Supply chain disruptions and inflationary pressures continue; product launches delayed to 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-001255","json":"https://secwatch.observer/filing/0001157523-21-001255.json","markdown":"https://secwatch.observer/filing/0001157523-21-001255.md","text":"https://secwatch.observer/filing/0001157523-21-001255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752321001255/0001157523-21-001255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752321001255/a52516018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T18:16:46.817628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}